Technical due diligence for Private equity investors & Banks

Technical due diligence for Private equity investors & Banks

For Private Equity investors and financial institutions, the billion-dollar question in any life sciences transaction is not just the target’s current revenue multiple—it is the hidden compliance liability lurking beneath the balance sheet. Undiscovered GMP deviations, data integrity breaches, pending Warning Letters, or aging facility infrastructure can erode enterprise value overnight and derail exit strategies.

Our Technical due diligence for Private equity investors & Banks service delivers an independent, forensic-grade risk assessment that bridges the critical gap between financial modeling and regulatory reality. We deploy seasoned GxP auditors, validation engineers, and former regulatory inspectors to conduct a systematic, costed examination of every value-impacting domain—including manufacturing facility and utility (PW/WFI, HVAC) conditions, computerized system (CSV/Part 11) compliance, equipment qualification status, process validation maturity, and quality management system (QMS) robustness. Crucially, we quantify the exact remediation investment, timeline, and operational disruption risk required to bring any non-compliant asset to full FDA/EMA conformance, factoring in potential supply chain bottlenecks and pending submission (IND/ANDA) success probabilities. Our reports are tailored specifically for investment committees and credit risk teams, translating complex technical observations into clear financial risk ratings, deal covenant recommendations, and post-acquisition integration roadmaps.

We also assess the competence of technical leadership and staffing depth to ensure the target can sustain compliance post-close. By uncovering “red flags” early and providing an objective, defensible valuation adjustment framework, we empower you to negotiate with confidence, protect portfolio value, and transform regulatory technicalities from a potential deal-breaker into a clearly understood, manageable investment variable.

Contact us now if you are looking for:

  • Due diligence for purchase / acquisitions
  • Techno-commercial asset evaluation for mergers and acquisitions
  • GMP Audits
  • Quality System Audits
  • Data Integrity Audits
  • Gap Assessments
  • Facility Compliance Remediation
  • Computer System Validation
  • Supplier/Vendor Audits
  • Warning Letter Response & Remediation
FAQs
A Greenfield project involves designing and constructing a new pharmaceutical facility from the ground up, while a Brownfield project focuses on expanding, upgrading, modernizing, or repurposing an existing facility. Both require careful planning to align operational goals with GMP and regulatory expectations.
Integrating GMP principles during project planning helps optimize facility layout, cleanroom design, utility systems, material and personnel flow, contamination control, and operational efficiency. Early planning can reduce costly redesigns, qualification delays, and compliance challenges later in the project lifecycle.
Project planning may include feasibility assessments, facility layout reviews, cleanroom zoning, utility planning, regulatory gap assessments, quality system design, SOP development, validation strategy, qualification planning, staffing support, training, and operational readiness activities.
A Brownfield assessment evaluates existing facilities, equipment, utilities, documentation, quality systems, and operational controls to identify compliance gaps, infrastructure limitations, remediation requirements, and potential risks that could impact future expansion, technology transfer, or regulatory inspections.
Quality systems, validation planning, and documentation strategies should ideally begin during the early design phase. Aligning QMS development, qualification activities, and validation requirements with construction and commissioning milestones helps support smoother project execution and operational readiness.
A Facility Readiness Review is a structured evaluation performed before commercial operations or regulatory inspections. It assesses facilities, utilities, documentation, validation status, training records, quality systems, and operational controls to determine preparedness for manufacturing activities and external audits.
Well-planned projects can provide scalable infrastructure, optimized workflows, flexible manufacturing capacity, improved compliance controls, and enhanced operational efficiency. These capabilities help organizations accommodate future product pipelines, market expansion strategies, and evolving regulatory requirements.
Common challenges include inadequate facility design, utility capacity constraints, poor workflow planning, qualification delays, documentation gaps, validation deficiencies, change management issues, project coordination challenges, and evolving regulatory expectations during implementation.
Yes. Comprehensive project planning can incorporate quality systems, validation programs, training initiatives, documentation controls, facility qualification, and readiness assessments designed to support a smoother transition into routine operations and future regulatory inspections.
External specialists can provide independent technical oversight, regulatory perspective, project management support, validation expertise, quality system guidance, and operational readiness planning. Their experience can help organizations identify risks early and improve project execution outcomes.
© 2026 GMP PHARMATECH. All rights reserved.